Immuno-virological and Clinical Follow-up of Persons With HIV-2 (PWHIV-2) Receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate (BIC/FTC/TAF): A Retrospective Study.

• Tác giả: Charlotte Charpentier, Mélanie Cresta, Florence Damond, Diane Descamps, Marc Digumber, Valentine M Ferré, Jade Ghosn, Véronique Joly, Quentin Le Hingrat, Sophie Matheron, Gilles Peytavin, Yazdan Yazdanpanah
• Ngôn ngữ: eng
• Ký hiệu phân loại: 372.89 History and geography
• Thông tin xuất bản: United States : Clinical infectious diseases : an official publication of the Infectious Diseases Society of America , 2025
• Bộ sưu tập: NCBI
• ID: 715261

Tóm tắt

 This retrospective study evaluated Bictegravir (BIC)/emtricitabine (FTC)/tenofovir alafenamide (TAF) in 24 persons with human immunodeficiency virus type 2 (HIV-2, PWHIV-2), 5 naive and 19 pretreated. After a median follow-up of 37.5 months, all PWHIV-2 had a plasma viral load <
 40 copies/mL. Median CD4 count increased significantly from 580 to 625 cells/mm3, suggesting the effectiveness of BIC/FTC/TAF to treat HIV-2 infection.